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Abstract
Atrial fibrillation (AF) is associated with a five-fold increased
risk for stroke due to cardioembolic events. Most strokes in
patients with AF arise from thrombus formation in the left
atrial appendage (LAA). Oral anticoagulation is a standard
treatment of AF patients with high risk of stroke. However,
the main drawbacks of oral anticoagulation are high risk of
major bleeding and imperfect effectiveness dependent on
a very narrow therapeutic range. In this article, based on two
case reports, we describe a method of percutaneous closure
of the LAA. We discuss indications, describe the procedure
and mention possible complications. LAA closure seems to
be a promising tool to prevent AF-related strokes in a select-
ed group of patients.
Key words: ischaemic stroke, left atrial appendage, antithrom-
botic therapy.
Percutaneous closure of the left atrial appendage to prevent ischaemic stroke 
in patients with atrial fibrillation who require but have contraindications 
to oral anticoagulation
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CASE REPORT/OPIS PRZYPADKU
St reszc zen ie
Migotanie przedsionków (atrial fibrillation – AF) zwiêksza
piêciokrotnie ryzyko wyst¹pienia udaru niedokrwiennego
mózgu. Wiêkszoœæ udarów w grupie osób z AF pochodzi ze
skrzeplin, które tworz¹ siê w uszku lewego przedsionka.
U pacjentów obci¹¿onych du¿ym ryzykiem standardem jest
stosowanie terapii przeciwkrzepliwej. Leczenie to ma jednak
istotne ograniczenia – zwiêksza ryzyko powa¿nych krwawieñ,
a jego skutecznoœæ czêsto jest nie najlepsza z powodu w¹skie-
go zakresu terapeutycznego. W artykule przedstawiono now¹
metodê, tj. zamkniêcie uszka lewego przedsionka technik¹
przez skórn¹, i opisano przypadki dwóch leczonych ni¹ pacjen-
tów. Autorzy okreœlili wskazania do zabiegu, jego przebieg,
a tak¿e mo¿liwe powik³ania. Przezskórne zamkniêcie uszka
lewego przedsionka  jest obiecuj¹c¹ metod¹ zapobie gania uda-
rom mózgu zwi¹zanym z AF w wyselekcjonowanej grupie
chorych.
S³owa kluczowe: udar niedokrwienny, uszko lewego przed-
sionka, terapia przeciwkrzepliwa. 
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Introduction
Atrial fibrillation (AF), a chaotic and irregular con-
traction of the atria, is the most common arrhythmia,
affecting 1-2% of the general population and resulting in
a significant number of hospitalizations. AF is associat-
ed with a five-fold increased risk of stroke due to car-
dioembolic events [1], being a substantial independent
risk factor regardless of whether it is paroxysmal or per-
manent. AF-related stroke results in significantly increased
mortality and morbidity when compared to non-AF caus-
es of stroke [2,3]. Most strokes in patients with AF arise
from thrombus formation in the left atrial appendage
(LAA) [4]. The pathogenesis is not fully understood but
relative stasis, which occurs in the appendage due to its
shape and the trabeculations within it, is thought to play
a major role [5]. Medical management with oral antico-
agulants is a standard treatment of AF patients with high
risk of stroke but its usefulness is limited due to high risk
of major bleeding and imperfect effectiveness of antico-
agulation dependent on a very narrow therapeutic range
demanding frequent monitoring and dose adjustments.
Even direct thrombin or Xa factor inhibitors, the most
recently developed drugs covering the latter drawback,
are still associated with bleeding risk and are therefore
contraindicated in high-risk patients.
For easier stratification of high-risk patients, two scales
have been developed recently. The CHA2DS2-VASc score
helps in assessment of stroke risk in non-valvular AF (see
Table 1). Those patients with one major risk factor or 
≥ 2 ‘clinically relevant non-major’ stroke risk factors (essen-
tially CHA2DS2-VASc score of ≥ 2) should be treated
with oral anticoagulation. If the patient obtains a maxi-
mum score of 9, the adjusted stroke rate (%/year) is 15.2%. 
Another useful tool is the HAS BLED scale – a new
simple bleeding risk score that allows assessment of
bleeding risk in AF patients. A score of ≥ 3 indicates
‘high risk’ and some caution and regular review of the
patient is needed following the initiation of antithrom-
botic therapy, whether with vitamin K antagonists or
aspirin. This scale is presented in Table 2.
Interventional techniques for occlusion of the LAA
represent a promising therapeutic option for stroke pre-
vention. These methods may be considered in patients
with AF who require anticoagulants, but have high 
risk of bleeding or in those with very labile INR levels. 
Several surgical techniques of LAA closure are being
employed with varying success rates in stroke risk reduc-
tion. When surgical LAA closure is performed, excision
of the appendage is the most reliable method. How ever,
there is ongoing concern about discontinuing anticoa -
gulation after surgical treatment due to the high rate of
unsuccessful closure [6].
The recent approach to close the LAA in high-risk
patients makes use of the transfemoral approach. The
first Polish experiences with the use of the Watchman
device were published in 2009 [7]. In our report, we
describe two patients with AF with high risk of both
thromboembolic stroke and bleeding complications who
were successfully treated via the percutaneous approach
using the new Amplatzer Cardiac Plug device.
Procedure description
The procedure is performed by an interventional car-
diologist in the catheterization laboratory with the use
Risk factor Patient 1 Patient 2
Congestive heart failure/ 0 1
LV dysfunction (1)
Hypertension (1) 1 1
Age ≥ 75 years (2) 2 2
Diabetes mellitus (1) 1 1
Stroke/TIA/thromboembolism (2) 2 2
Vascular disease (1) 1 0
Age 65-74 years (1) 0 0
Sex category (i.e. female sex) (1) 1 1
Total score (maximum, 9) 8 8
Table 1. CHA2DS2-VASc Score. Maximum score is shown in brackets. 
Score for both patients was calculated
LV – left ventricle, TIA – transient ischaemic attack
Risk factor Patient 1 Patient 2
Hypertension (1) 1 1
Abnormal renal and liver function 1 0
(1 point each)
Stroke (1) 1 0
Bleeding (1) 0 1
Labile INRs (1) 0 0
Elderly (e.g. age > 65 years) (1) 1 1
Drugs or alcohol (1 point each) 0 0
Total score (maximum, 9) 4 3
Table 2. HAS BLED scale. Score is shown in brackets. Score for both patients
was calculated
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of fluoroscopy. The presence of an echocardiographer,
anaesthesiologist and assisting nurse is essential. Clo-
sure of the appendage is performed in general anaes-
thesia. To begin, the femoral vein is punctured and
a sheath is inserted. Next the puncture of the atrial sep-
tum is performed under X-ray control and with the
assistance of transoesophageal echocardiography (TEE).
There is no need to perform this step in the case of
patent foramen ovale, or atrial septal defect. After cross-
ing to the left atrium with the catheter, measurements
of the appendage with dye injection are made (Fig. 1).
Subsequently, the occluder may be transferred to 
the appendage with echo measurements (Fig. 2). The
implant is placed in the orifice of the LAA, preventing
the passage of thrombi into the arterial circulation. After
checking its stable position, the mechanism is released
and catheters are withdrawn. Figure 3 shows a transo -
esophageal echocardiographic image of the occluder.
After the procedure, the patient usually remains supine
for four hours to prevent local complications after punc-
ture of the vein and insertion of large sheaths.
Case reports
Patient 1
An 80-year-old woman presented with hypertension,
paroxysmal AF and a history of ischaemic stroke three
years ago and upper gastrointestinal bleeding. On the
CHA2DS2VASc scale she scored 8 points, which trans-
lates to 6.7% yearly risk of ischaemic stroke (Table 1).
On the HAS BLED scale she scored 4 points (Table 2),
indicating significantly increased risk of bleeding on oral
anticoagulation.
We performed obliteration of the LAA with a right
femoral vein approach to the venous system. After inter-
atrial septum puncture with TEE guidance and serial
measurements, a 20-mm Amplatzer Cardiac Plug device
was chosen. After placing the device in the LAA orifice
securely, the mechanism was successfully released with
no complications. The impermeability was checked with
contrast dye under fluoroscopy. The patient was dis-
charged home a few days after the occlusion with advice
LAA – left atrial appendage
Fig. 1. The dye is injected through the catheter to the left atrial appendage 
TEE – transoesophageal echocardiography, LAA – left atrial appendage
Fig. 2. Proper placement of occluder in ostium of left atrial appendage. 
The dye does not cross to the appendage; thus the structure is successfully 
excluded 
LAA – left atrial appendage
Fig. 3. Transoesophageal echocardiography image of the appendage closed
by the occluder. Three-month follow-up study
Neurologia i Neurochirurgia Polska 2012; 46, 190
to continue both aspirin (75 mg daily) and clopidogrel
(75 mg daily) for 6 months. Endocarditis prophylaxis
was advised. At three-month follow-up the patient
remained well with no complications and no further
cerebrovascular accidents. TEE revealed good place-
ment of the device within the LAA. 
Patient 2
A 78-year-old woman presented with hypertension,
diabetes on oral medication, long history of persistent 
AF and ischaemic stroke with haemorrhagic transfor-
mation in September 2010. CHA2DS2-VASc score 
was 8 points (Table 1) and HAS BLED score was 3 
(Table 2). In echocardiography, left ventricle ejection
fraction was slightly diminished and concentric heart
hypertrophy was present.
The LAA was approached via the right transfemoral
route. Due to presence of patent foramen ovale, punc-
ture of the septum was not necessary. Following serial
measurements, the Amplatzer Cardiac Plug 26 mm was
chosen to obliterate the orifice of the appendage. After
performing a stability test, the device was released. There
were no complications and the procedure was complet-
ed successfully. Four days later patient was discharged
home. The patient received aspirin (75 mg daily) and
clopidogrel (75 mg daily) only for one month due to 
relative contraindications to longer, 6-month therapy.
Endocarditis prophylaxis was advised. After 3 months,
TEE revealed good placement of the device within the
LAA and presence of a minor thrombus on the atrial
disc of the device, which completely resolved after 
4 weeks of therapy with low molecular weight heparin.
Discussion
Oral anticoagulation with vitamin K antagonist
(VKA) is the mainstay in stroke prevention in AF
patients, but there are several drawbacks. Most impor-
tant is increased bleeding risk, particularly with INR
values > 3.5-4.0. Chronic treatment with oral antico-
agulant necessitates regular anticoagulation monitoring
and dose adjustment. Multiple interactions with other
drugs and food hamper use of VKA. Especially in elder-
ly patients anticoagulation monitoring can be difficult
and this age group is prone to higher bleeding risk [8].
In addition, patients on VKA appear to be undertreat-
ed for at least one third of time with the INR value
remaining below the therapeutic range [9]. Novel long-
expected anticoagulants, direct thrombin or Xa factor
antagonist, seem to cover the inconvenience related to
regular anticoagulation monitoring with at least the same
efficacy as VKA [10], but the bleeding risk is still pre-
sent. Therefore pursuing a new, non-pharmacological
approach is more than justified. 
Recently, important data regarding efficacy and sa -
fety of percutaneous LAA closure have been releas ed.
A randomized controlled trial of 707 patients treated
with percutaneous closure of the LAA (n = 463) or
warfarin (n = 244) reported all-cause strokes per 
100 patient-years of 2.3 and 3.2, respectively (rate ratio
0.71, credible interval [CrI] 0.35 to 1.64). The effica-
cy of percutaneous closure of the LAA with this device
was non-inferior to that of warfarin therapy. Successful
closure was reported in 88% (408/463) of patients [11].
In a case series of 111 patients, stroke was noted in 
2 patients at 173- and 215-day follow-up. In both
patients, TEE performed at 1 and 6 months revealed
a stable device with no thrombogenic layer on the sur-
face. Those findings led to the suggestion that closing
the LAA may become an alternative in patients with AF
and a contraindication for lifelong anticoagulation treat-
ment [12].
Regarding the safety of LAA closure, few severe car-
diac complications have been reported. Tamponade
requiring median sternotomy, pericardiocentesis and 
ligation of the LAA occurred in 1 patient 4 hours after
the procedure in the case series of 111 patients cited
above. This patient later developed deep vein thrombo-
sis and died 27 days after the procedure, which was
attributed to cerebral haemorrhage associated with anti-
coagulation therapy. Holmes et al. reported pericardial
effusion successfully treated surgically or with pericar-
diocentesis in 5% of patients (22/463), and pericardial
effusion not requiring drainage in 2% (8/463) of pa -
tients. Cardiac arrest 30 minutes after the procedure
because of device embolisation was reported in 1 patient,
who subsequently died, in a case series of 73 patients
[13]. Other potential complications of LAA closure
include local bleeding, embolisation, endocarditis,
arrhythmia, stroke and transient ischaemic attack (TIA).
Nevertheless, all of those remain rarely reported until
now. We did not experience complications or major dif-
ficulties when performing the closure of LAA in both
our patients.
Apparently, percutaneous LAA closure is not an
alternative for all patients with AF who require antico-
agulation but appears to be a therapeutic option for
patients with very high risk of bleeding. One can assume
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that it will become more common as the population of
patients with AF who require other than pharmacolo -
gical treatment is rapidly growing.
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